Acorda Therapeutics, Inc. (ACORQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acorda Therapeutics, Inc. (ACORQ) with AI Score 42/100 (Weak). Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Acorda Therapeutics, Inc. (ACORQ) Healthcare & Pipeline Overview
Acorda Therapeutics, Inc. develops and commercializes therapies for neurological disorders, including Ampyra for multiple sclerosis and Inbrija for Parkinson's disease. Facing financial challenges, the company filed for Chapter 11 bankruptcy in 2024 and now operates in the OTC market, impacting its market capitalization and investor accessibility.
Investment Thesis
Investing in Acorda Therapeutics, Inc. (ACORQ) presents substantial risks due to its Chapter 11 bankruptcy filing in April 2024. The company's future hinges on the successful restructuring of its debt and operations. Key value drivers include the continued sales of Ampyra and Inbrija, though these are subject to market competition and pricing pressures. Growth catalysts are limited given the bankruptcy status, but potential restructuring plans and strategic asset sales could unlock value. Investors should closely monitor the bankruptcy proceedings and any announcements regarding the company's long-term strategy. The company's negative profit margin of -215.0% and its current trading status on the OTC market further underscore the high-risk nature of this investment.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B reflects the company's distressed financial state following its Chapter 11 filing.
- Profit margin of -215.0% indicates significant losses and operational challenges.
- Gross margin of 60.9% suggests that the company's core products retain some profitability before accounting for operating expenses and debt servicing.
- Beta of 1.69 indicates higher volatility compared to the broader market, reflecting the uncertainty surrounding the company's future.
- Chapter 11 bankruptcy filing on April 1, 2024, represents a critical turning point for the company's operations and financial structure.
Competitors & Peers
Strengths
- Established products in the market for neurological disorders (Ampyra and Inbrija).
- Collaboration agreement with Biogen Inc. for Ampyra.
- Gross margin of 60.9% indicates potential profitability at the product level.
Weaknesses
- Chapter 11 bankruptcy filing indicates severe financial distress.
- Negative profit margin of -215.0% reflects significant losses.
- High debt burden and ongoing restructuring efforts.
- Trading on the OTC market limits liquidity and investor access.
Catalysts
- Upcoming: Bankruptcy court decisions regarding restructuring plan.
- Upcoming: Potential asset sales or licensing agreements.
- Ongoing: Continued sales of Ampyra and Inbrija.
- Ongoing: Efforts to reduce operating expenses and improve efficiency.
Risks
- Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.
- Potential: Generic competition for Ampyra and Inbrija.
- Potential: Pricing pressures and reimbursement challenges.
- Potential: Regulatory hurdles and delays in drug approvals.
- Ongoing: Limited liquidity and price volatility due to OTC trading.
Growth Opportunities
- Restructuring and Debt Resolution: Acorda's primary growth opportunity lies in successfully restructuring its debt and emerging from Chapter 11 bankruptcy. A favorable restructuring plan could alleviate financial pressures and allow the company to focus on its core products, Ampyra and Inbrija. The timeline for this is dependent on the bankruptcy court's decisions, but a resolution within the next 12-18 months is crucial for the company's survival.
- Strategic Asset Sales: Acorda could explore selling non-core assets or licensing agreements to generate capital and streamline operations. This could involve divesting certain product lines or partnering with other pharmaceutical companies to expand the market reach of its existing therapies. The success of this strategy depends on identifying suitable assets and securing favorable terms, with potential deals materializing within the next 6-12 months.
- Expansion of Inbrija Market: Despite its financial challenges, Acorda could focus on expanding the market for Inbrija, its inhaled levodopa treatment for Parkinson's disease. This could involve increasing awareness among physicians and patients, conducting further clinical trials to support new indications, and exploring partnerships to expand its distribution network. The market for Parkinson's disease treatments is growing, presenting a significant opportunity for Inbrija.
- Geographic Expansion: While facing bankruptcy, Acorda could explore opportunities to expand its geographic reach, particularly in emerging markets where there is unmet need for neurological disorder treatments. This could involve partnering with local distributors or licensing its products to companies with established market presence. However, this strategy would require significant investment and careful market analysis.
- New Product Development: Although financially constrained, Acorda could invest in developing new therapies for neurological disorders. This could involve focusing on early-stage research and development projects or acquiring promising drug candidates from other companies. However, this strategy is highly risky and would require significant capital investment, making it a longer-term growth opportunity.
Opportunities
- Successful restructuring of debt and emergence from Chapter 11.
- Strategic asset sales to generate capital.
- Expansion of Inbrija market and potential new indications.
- Geographic expansion into emerging markets.
Threats
- Generic competition for Ampyra and Inbrija.
- Pricing pressures and reimbursement challenges.
- Regulatory hurdles and potential delays in drug approvals.
- Uncertainty surrounding the bankruptcy proceedings and potential liquidation.
Competitive Advantages
- Patent protection for its key products, such as Ampyra and Inbrija, provides a degree of market exclusivity.
- Established relationships with healthcare providers and distributors.
- Brand recognition and reputation in the neurological disorder treatment market.
About ACORQ
Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Pearl River, New York. The company focuses on developing and commercializing therapies for neurological disorders. Its primary products include Ampyra (dalfampridine), an oral medication designed to improve walking in adults with multiple sclerosis, and Inbrija, an inhaled levodopa formulation used for the intermittent treatment of OFF periods in individuals with Parkinson's disease who are already being treated with a carbidopa/levodopa regimen. Acorda also markets Ampyra as Fampyra in Europe, Asia, and the Americas through partnerships. A significant collaboration for Acorda is its license agreement with Biogen Inc. for the development and commercialization of Ampyra. However, on April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York, reflecting substantial financial distress. This event has significantly altered the company's operational and financial landscape.
What They Do
- Develops and commercializes therapies for neurological disorders.
- Markets Ampyra (dalfampridine) to improve walking in adults with multiple sclerosis.
- Markets Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease.
- Sells Ampyra as Fampyra in Europe, Asia, and the Americas through partnerships.
- Collaborates with Biogen Inc. for the development and commercialization of Ampyra.
- Navigates regulatory approval processes for its pharmaceutical products.
Business Model
- Develops pharmaceutical products for neurological disorders.
- Commercializes and markets these products directly or through partnerships.
- Generates revenue through sales of its pharmaceutical products, primarily Ampyra and Inbrija.
Industry Context
Acorda Therapeutics operates within the specialty pharmaceutical sector, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for neurological disorder treatments is substantial, driven by an aging population and increasing prevalence of conditions like multiple sclerosis and Parkinson's disease. However, the industry is also marked by patent expirations, generic competition, and pricing pressures. Acorda's bankruptcy reflects the challenges faced by smaller pharmaceutical companies in sustaining profitability and managing debt in this environment. Competitors like CBDHF, CHCR, GDBYF, GENN, and GNBT also operate in this space, facing similar market dynamics.
Key Customers
- Adults with multiple sclerosis who use Ampyra to improve walking.
- People with Parkinson's disease treated with a carbidopa/levodopa regimen who use Inbrija for OFF periods.
- Healthcare providers who prescribe Acorda's medications to their patients.
Financials
Chart & Info
Acorda Therapeutics, Inc. (ACORQ) stock price: Price data unavailable
Latest News
No recent news available for ACORQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACORQ.
Price Targets
Wall Street price target analysis for ACORQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates ACORQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ron Cohen
CEO
Ron Cohen has served as the CEO of Acorda Therapeutics, Inc. He has extensive experience in the biotechnology and pharmaceutical industries. His background includes leadership roles in various companies focused on neurological disorders. Cohen's expertise spans drug development, commercialization, and corporate strategy. He has been instrumental in guiding Acorda through various stages of growth and challenges, including the development and launch of Ampyra and Inbrija. His leadership is critical as the company navigates its Chapter 11 restructuring.
Track Record: Under Ron Cohen's leadership, Acorda Therapeutics successfully developed and commercialized Ampyra and Inbrija. He oversaw the company's collaboration with Biogen Inc. for Ampyra. However, his tenure also saw the company face significant financial challenges, culminating in the Chapter 11 bankruptcy filing in April 2024. The success of the restructuring efforts will be a key indicator of his leadership during this critical period.
ACORQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acorda Therapeutics does not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often face significant financial distress, regulatory issues, or lack of transparency. Trading on the OTC Other tier typically involves higher risks due to limited information and potential for manipulation compared to stocks listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and potential for price volatility due to OTC trading.
- Lack of consistent financial reporting and transparency.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Chapter 11 bankruptcy proceedings create significant uncertainty.
- Potential for delisting and loss of investment.
- Review bankruptcy filings and court documents.
- Assess the company's restructuring plan and prospects for emerging from Chapter 11.
- Evaluate the company's remaining assets and potential for asset sales.
- Monitor news and press releases for updates on the company's financial condition.
- Consult with a financial advisor to assess the risks and potential rewards.
- Verify the company's legal and regulatory compliance.
- Understand the terms and conditions of trading OTC stocks.
- Existing products (Ampyra and Inbrija) with established market presence.
- Collaboration agreement with Biogen Inc. for Ampyra.
- History of operating as a publicly traded company prior to bankruptcy.
- Continued operations during the bankruptcy proceedings.
- Engagement of legal and financial advisors for the restructuring process.
ACORQ Healthcare Stock FAQ
What does Acorda Therapeutics, Inc. do?
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Its primary products are Ampyra (dalfampridine), used to improve walking in adults with multiple sclerosis, and Inbrija, an inhaled levodopa treatment for OFF periods in Parkinson's disease patients. The company markets these products in the United States and, through partnerships, in other regions. However, Acorda filed for Chapter 11 bankruptcy in April 2024 and now trades on the OTC market, reflecting significant financial challenges.
What do analysts say about ACORQ stock?
Given Acorda Therapeutics' Chapter 11 bankruptcy filing and its current trading status on the OTC market, formal analyst coverage is likely limited. Key valuation metrics such as price-to-earnings ratio are not meaningful due to the company's negative profitability. Any investment considerations should focus on the potential for successful restructuring, asset sales, and the long-term viability of its core products, Ampyra and Inbrija. Investors should conduct thorough due diligence and consult with a financial advisor before investing.
What are the main risks for ACORQ?
The primary risks for Acorda Therapeutics stem from its Chapter 11 bankruptcy proceedings. These include the potential for liquidation, dilution of existing shareholders, and uncertainty surrounding the company's future operations. Additional risks include generic competition for Ampyra and Inbrija, pricing pressures, regulatory hurdles, and the limited liquidity associated with trading on the OTC market. The company's ability to successfully restructure its debt and emerge from bankruptcy is critical to its survival.
What are the key factors to evaluate for ACORQ?
Acorda Therapeutics, Inc. (ACORQ) currently holds an AI score of 42/100, indicating low score. Key strength: Established products in the market for neurological disorders (Ampyra and Inbrija).. Primary risk to monitor: Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.. This is not financial advice.
How frequently does ACORQ data refresh on this page?
ACORQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ACORQ's recent stock price performance?
Recent price movement in Acorda Therapeutics, Inc. (ACORQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established products in the market for neurological disorders (Ampyra and Inbrija).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ACORQ overvalued or undervalued right now?
Determining whether Acorda Therapeutics, Inc. (ACORQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ACORQ?
Before investing in Acorda Therapeutics, Inc. (ACORQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change due to the ongoing bankruptcy proceedings.
- OTC market data may be limited or unreliable.